Polyazamacrocycle Ligands Facilitate ⁸⁹Zr Radiochemistry and Yield ⁸⁹Zr Complexes with Remarkable Stability.

ABSTRACT: Over the last three decades, the chemistry of zirconium has facilitated antibody development and the clinical management of disease in the precision medicine era. Scientists have harnessed its reactivity, coordination chemistry, and nuclear chemistry to develop antibody-based radiopharmaceuticals incorporating zirconium-89 (⁸⁹Zr: t_1/2 = 78.4 h, β⁺: 22.8%, E_β+max = 901 keV; EC: 77%, E_γ = 909 keV) to improve disease detection, identify patients for individualized therapeutic interventions. and monitor their response to those interventions. However, release of the ⁸⁹Zr⁴⁺ ion from the radiopharmaceutical remains a concern, since it may confound the interpretation of clinical imaging data, negative

SUBMITTER: Pandya DN 

PROVIDER: S-EPMC8300002 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature